Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism

Osteoporosis International

Volumn 26, Issue 4, 2015, Pages 1295-1302

  Cesareo, R ^a   Di Stasio, E ^b   Vescini, F ^c   Campagna, G ^a   Cianni, R ^a   Pasqualini, V ^a   Romitelli, F ^b   Grimaldi, F ^c   Manfrini, S ^d   Palermo, A ^d  

^a SANTA MARIA GORETTI HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Alendronate; Bone mineral density; Bone turnover markers; Normocalcemic primary hyperparathyroidism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID PLUS COLECALCIFEROL; CALCIUM; COLECALCIFEROL; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; DRUG COMBINATION;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MIDDLE AGED; MORNING DOSAGE; NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; FEMUR; HYPERPARATHYROIDISM, PRIMARY; LUMBAR VERTEBRA; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; DRUG COMBINATIONS; FEMALE; FEMUR; HUMANS; HYPERPARATHYROIDISM, PRIMARY; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES;

EID: 84928317034     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-3000-2     Document Type: Article

References (45)

1. Fraser WD (2009) Hyperparathyroidism. Lancet 374:145–158
2. Cope O (1966) The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 274:1174–1182
3. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):351–365
4. Silverberg SJ1, Bilezikian JP (2006) The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2:494–503
5. Bollerslev J, Marcocci C, Sosa M, Nordenstrom J, Bouillon R, Mosekilde L (2011) Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol 165(6):851–864
6. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569
7. Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339
8. Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648
9. Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348–5352
10. Bilezikian JP, Silverberg SJ (2010) Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metab 54(2):106–109
11. Cusano N, Silverberg SJ, Bilezikian JP (2013) Normocalcemic primary hyperparathyroidism. J Clin Densitom 16:33–39
12. Eastell R, Brandi M, Costa AG, D’Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asyntomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99:3570–3579
13. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 1:861–863
14. Garcia-Martin AR-GR, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42:764–766
15. Balsa JA, Botella-Carretero JI, Peromingo R, Zamarron I, Arrieta F, Munoz-Malo T, Vazquez C (2008) Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Investig 31:845–850
16. Selby PL, Davies M, Adams JE, Mawer EB (1999) Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 14:652–657
17. Lowe H, McMahon DJ, Rubin MR et al (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001–3005
18. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N (2004) Characterization of normocalcemic primary hyperparathyroidism. Am J Med 117:861–863
19. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352
20. Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36:761–766
21. Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP (2006) Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 91:1748–1753
22. Udelsman R, Akerstrom G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F (2014) The surgical managment of asyntomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99:3595–3606
23. Sankaran S, Gamble G, Bolland M, Reid IR, Grey A (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 95(4):1653–1662
24. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470
25. LoCascio V, Adami S, Galvanini G, Ferrari M, Cominacini L, Tartarotti D (1985) Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism. N Engl J Med 313:1123–1125
26. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90(4):2122–2126. doi:10.1210/jc.2004-1772
27. Isidro ML, Ruano B (2009) Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 36:305–310
28. Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99:1072–1080
29. Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND (2008) Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 144:852–858, discussion 858–859
30. Tucci JR (2009) Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 161:189–193
31. Kantorovich V, Gacad MA, Seeger LL, Adams JS (2000) Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 85:3541–3543
32. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360–368
33. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S (2001) Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16:113–119
34. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW, Cockram CS (2003) Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:581–587
35. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:3319–3325
36. Montomoli M, Gonnelli S, Mattei R, Cuda C, Rossi S, Gennari C (2002) Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian women. Eur J Clin Nutr 56:21–30
37. Rao DS, Wilson R, Kleerekoper M, Parfitt A (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298
38. Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA (2009) Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract 15:705–713
39. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Group FR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938
40. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541
41. Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, Reid DM, Secombes KR, Simpson WG, Thies F (2013) Hip bone loss is attenuated with 1000 UI but not 400 UI daily vitamin D3: 1 year double blind RCT in postmenopausal women. J Bone Miner Res 28:2202–2213
42. Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC (2006) Alendronate with and without cholecalciferol for osteoporosis: results of a 15 week randomized controlled trial. Curr Med Res Opin 22:1745–1755
43. Raimundo FV, Faulharber GA, Menegatti PK, Marques LS, Furlanetto TW (2011) Effect of high- versus low-fat meal on serum 25-hydroxyvitamin d levels after a single oral dose of vitamin D: a single-blind, parallel, randomized trial. Int J Endocrinol 2011. doi:10.1155/2011/809069.
44. Heaney RP, Chen TC, Holick MF, Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77:204–210
45. Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080S–1086S